FDA in Transition: How Regulatory Shifts Are Redefining Drug Development
The uncertainty surrounding changes at the FDA and other market dynamics is reshaping the global drug development landscape. In this webinar, CRO regu...
Scrip's Five Must-Know Things - 26 May 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended 23 May 2025. In this episode: Novo Nordisk’s CEO forced o...
Drug Fix: US FDA’s Big Vaccine Policy Week
Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the...
“Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement syst...
제약바이오딜 투자수익률 하락…시장 불안정으로 상황 악화될 수도 (Korean-language podcast)
바이오기업 가치상승으로 일부 딜 (deal)의 경우 빅파마의 투자수익률 (ROI)이 거의 없는 상황이지만, 특정 전략으로 성공 가능성을 높일 수 있다는 Scrip 기사를 요약한 내용입니다. https://insights.citeline.com/scrip/busines...
Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer
While few doubt the opportunity represented by real-world evidence, some concerns remain about its validity compared to traditional forms of clinical ...
Scrip's Five Must-Know Things - 19 May 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended 16 May 2025. In this episode: Trump’s executive order mor...
China Biopharma Podcast - 14 May 2025 (Chinese language)
在本期中国生物技术播客中，Dexter Yan回顾了他在4月的美国癌症研究协会年会（AACR）举办前和再鼎医药总裁及全球肿瘤研发负责人Rafael Amado的采访。Amado在采访中详细阐述再鼎在AACR展示的两个临床前项目，分别是PD-1/IL-12 双抗和靶向LRRC15的抗体偶联药物（ADC...
Scrip's Five Must-Know Things - 12 May 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended 9 May 2025. In this episode: industry makes its case to T...
Drug Fix: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider early excitement and concern about Vi...